Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.61 |
| ▸ | GFER | P55789 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | POLB | P06746 | 5/20 | 0.57 |
| ▸ | USP2 | O75604 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8174405 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL7653231 | 0.88 | SMN1; SMN2 (0.56) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL7652952 | 0.88 | SMN1; SMN2 (0.56) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8130397 | 0.87 | MEN1 (0.65) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL27442744 | 0.86 | NPC1 (0.70) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL412846 | 0.85 | MEN1 (0.74) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8148043 | 0.84 | NPC1 (0.75) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL12175141 | 0.84 | DGAT1 (0.62) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL13299660 | 0.84 | NPC1 (0.72) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL9112601 | 0.83 | PRMT1 (0.68) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399642-B2 | TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-06-04 | — | — | US | disclosed |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-07-26 | — | — | US | disclosed |
| US-6221892-B1 | Heterocyclic topoisomerase poisons | THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS | 2001-04-24 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | TOP1, TOP2A, TOP2B | KDM4E 2275/4885ALDH1A1 2485/4885MAPT 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.